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Unexpected cell type-dependent effects of
autophagy on polyglutamine aggregation
revealed by natural genetic variation in
C. elegans
J. Alexander-Floyd1,2, S. Haroon3, M. Ying1, A. A. Entezari1,4, C. Jaeger1,5, M. Vermulst3,6 and T. Gidalevitz1*
Abstract
Background: Monogenic protein aggregation diseases, in addition to cell selectivity, exhibit clinical variation in the
age of onset and progression, driven in part by inter-individual genetic variation. While natural genetic variants may
pinpoint plastic networks amenable to intervention, the mechanisms by which they impact individual susceptibility
to proteotoxicity are still largely unknown.
Results: We have previously shown that natural variation modifies polyglutamine (polyQ) aggregation phenotypes
in C. elegans muscle cells. Here, we find that a genomic locus from C. elegans wild isolate DR1350 causes two
genetically separable aggregation phenotypes, without changing the basal activity of muscle proteostasis pathways
known to affect polyQ aggregation. We find that the increased aggregation phenotype was due to regulatory
variants in the gene encoding a conserved autophagy protein ATG-5. The atg-5 gene itself conferred dosage-
dependent enhancement of aggregation, with the DR1350-derived allele behaving as hypermorph. Surprisingly,
increased aggregation in animals carrying the modifier locus was accompanied by enhanced autophagy activation
in response to activating treatment. Because autophagy is expected to clear, not increase, protein aggregates, we
activated autophagy in three different polyQ models and found a striking tissue-dependent effect: activation of
autophagy decreased polyQ aggregation in neurons and intestine, but increased it in the muscle cells.
Conclusions: Our data show that cryptic natural variants in genes encoding proteostasis components, although
not causing detectable phenotypes in wild-type individuals, can have profound effects on aggregation-prone
proteins. Clinical applications of autophagy activators for aggregation diseases may need to consider the
unexpected divergent effects of autophagy in different cell types.
Keywords: Natural genetic variation, Regulatory variation, Cryptic variation, Protein aggregation, Proteostasis,
Polyglutamine, Autophagy
Background
Protein misfolding and aggregation underlie many hu-
man diseases and contribute to tissue decline during
aging [1, 2]. In familial cases, the disease-causing muta-
tions are often directly responsible for misfolding and
aggregation of the mutant protein [3, 4]. For example,
expansions of the CAG repeats in several different dis-
eases lead to expanded polyglutamine (polyQ) tracts in
affected proteins, which in turn result in their increased
aggregation propensity [5–7]. Such mutations exhibit
“toxic gain-of-function” behavior and thus a dominant,
monogenic inheritance pattern. The mechanisms
explaining the gain-of-function toxicity are still incom-
pletely understood. Two aspects of protein aggregation
diseases may contribute to this difficulty. First, the be-
havior of mutant proteins appears to depend on the cel-
lular environment: although they are often expressed
broadly or even ubiquitously, only select subsets of cells
are affected in each disease [8, 9]. Second, these diseases
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show variation in the age of onset, severity, or clinical phe-
notypes [10]. The variation is thought to result, in addition
to stochastic and environmental factors, from variants
present in individual’s genetic background that act as
modifiers [11–13]. These genetic modifiers can affect pro-
teins and regulatory pathways that either interact with the
disease-causing mutant proteins, or are themselves im-
pacted in disease [14]. Therefore, identifying natural
modifier variants and their mechanisms can expand our
understanding of cellular pathways involved in disease.
Natural variants may also indicate pathways that differ
from those found by the traditional approaches such as as-
sociation studies, mutagenesis, or RNAi screens. Import-
antly, because these modifiers are a part of natural genetic
variation and are present in phenotypically normal indi-
viduals, they may pinpoint therapeutic routes that are less
likely to cause detrimental side effects.
The most informative way to map genetic modifiers of
disease is directly in human patients [13]. A number of
studies found that genetic variants other than those con-
trolling the CAG repeat size of the polyQ-expanded hun-
tingtin (Htt) are capable of modifying the pathogenesis of
Huntington’s disease (HD) [12, 15–18]. Two recent large
studies have identified four loci on chromosomes 3, 8, and
15 in HD subjects of European ancestry, and a locus on
chromosome 7 in a Venezuelan HD cluster [19–21]. The
modifier locus in Venezuelan HD may act by a novel
mechanism—regulating the bone morphogenetic protein
signaling, while pathway analysis in European HD impli-
cated DNA repair pathways, which are thought to act by
changing the size of the CAG repeat itself. The difficulties
in using human patients in search for modifiers across ag-
gregation diseases include the size and complexity of the
human genome, the often small size of affected popula-
tions, and the possibility of complex interactions among
multiple modifiers [10, 13, 22]. Human studies may also
have limited ability to identify modifiers that are rare, or
segregate in families rather than in entire affected popula-
tions. Model organisms offer a genetically tractable alter-
native due to the evolutionary conservation of the main
cellular pathways. Expression of disease-related proteins
in these organisms recapitulate many characteristics of
human diseases that are related to the basic biology of
protein misfolding and aggregation [23]. For example, C.
elegans and Drosophila models expressing polyQ-
expanded Htt or ataxin-3, or isolated polyglutamine re-
peats, exhibit similar toxic gain-of-function behavior and
the age- and polyQ-length-dependent aggregation and
toxicity as those seen in patients and in mammalian
models [24–34]. Many candidate modifying pathways
identified in model organisms proved to be conserved, in-
cluding insulin signaling, the heat-shock response, or reg-
ulators of proteostasis [35]. Importantly, as in human
disease, polyQ expansions in C. elegans also exhibit
dependence on both the cellular environment [30, 36, 37]
and the genetic background [38], despite their dominant
gain-of-function behavior. We have previously shown that
genetic variants coding for marginally stable proteins, al-
though innocuous under normal conditions, can dramat-
ically change both the aggregation and the associated
toxicity of the aggregation-prone proteins, suggesting that
genetic variation may directly impinge on cellular proteos-
tasis [37, 39]. Indeed, introduction of natural variation into
the genetic background of polyQ-expressing animals inde-
pendently modified several different aspects of polyQ be-
havior, including the onset and extent of aggregation, the
susceptibility of different types of muscle cells to aggrega-
tion, and the resulting loss of motility and shortened life-
span [38]. The polyQ aggregation in these genetically
variable animals showed transgressive segregation, indicat-
ing that multiple additive or interacting alleles in parental
backgrounds were acting as modifiers [38]. A recent study
has shown that natural variation also modulates the phe-
notypes caused by expression of α-synuclein transgene in
the body-wall muscle cells of C. elegans [40]. Thus, natural
genetic variation within C. elegans wild strains can be used
to investigate the mechanisms and pathways controlling
the toxic effects of protein misfolding and aggregation.
Here, we dissected the genetic variation causing increased
aggregation of the muscle-expressed 40-residue polyQ ex-
pansion (Q40::YFP, or Q40) in the background of a Califor-
nian wild strain of C. elegans, DR1350 [38]. We identified a
large modifier locus on chromosome I as being causal for
two phenotypes: altered susceptibility of the head muscle
cells to aggregation and increased overall aggregation.
These phenotypes were genetically separable, and we iden-
tified regulatory variants in a gene encoding a conserved
autophagy protein ATG-5 as being responsible for the latter
phenotype. The atg-5 gene conferred a dosage-dependent
enhancement of polyQ aggregation, with DR1350-derived
atg-5 allele behaving as a hypermorph. Surprisingly, animals
bearing the variant atg-5 allele showed enhanced response
to an autophagy-activating drug. Because autophagy is ex-
pected to clear polyQ aggregates, we tested the effect of dir-
ectly activating autophagy on the polyQ aggregation in our
model, and found a striking tissue dependence for the effect
of autophagy on polyQ aggregation. Our data show that
cryptic genetic variants in genes encoding proteostasis
components can have profound effects on the behavior of
aggregation-prone proteins, and suggest that activation of
autophagy may have divergent effects on the clearance of
such proteins in different cell types.
Results
DR1350-derived variants increase polyglutamine
aggregation
We previously found that introgression of an integrated
polyglutamine-encoding transgene (Q40) from the
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laboratory Bristol/N2 background (Q40Bristol) into the
wild California isolate DR1350 resulted in strongly accel-
erated polyglutamine aggregation in the body-wall
muscle cells, and a characteristic switch in the relative
susceptibility of the normally resistant head muscle cells
to polyQ aggregation [38]. These two phenotypes were
also present in 5 out of 21 recombinant inbred lines
(RILs) derived from a cross between Q40Bristol and
Q40DR1350 strains [38]. The DR1350 parent belongs to
the isotype defined by the California-derived strain
CB4853 (the Caenorhabditis elegans Natural Diversity
Resource [41]). Both strains have been used in some of
the earliest studies on the effects of natural variation on
phenotypic traits [42, 43], and DR1350 was also used to
map quantitative trait loci (QTL) that control pheno-
typic responses to environmental stress [44]. Interest-
ingly, genetic variation between DR1350 (or CB4853)
and Bristol/N2 strains is unequally distributed across the
chromosomes in C. elegans [41, 44, 45].
To isolate the genetic variation that contributed to in-
creased aggregation, we chose one (RIL2) that exhibited
more than twofold increase in the number of aggregates
relative to the Q40Bristol parent at the late fourth larval
stage (L4) (Fig. 1a). We backcrossed RIL2 animals to the
Q40Bristol parental strain 23 times, selecting for the F2
progeny that inherited RIL2-like phenotypes after each
round of backcrossing (Fig. 1b). This approach ensured
that the DR1350-derived variants that contributed to the
polyQ phenotypes were retained in the resulting 23×
backcrossed strain, while the majority of its background
was derived from the Q40Bristol parental strain. The
backcrossed strain is referred to as drxIR1;Q40 (Fig. 1b).
Since the increased susceptibility of the head muscles is
an easy to detect qualitative phenotype that behaved in
our RIL panel as a recessive trait [38], we used this
phenotype during F2 progeny selection. Interestingly,
the drxIR1;Q40 strain also retained the second polyQ
phenotype—increased overall aggregation (Fig. 1a, c),
Fig. 1. drxIR1 locus causes increased polyQ40 aggregation. a Late-L4 RIL2 and drxlR1;Q40 animals have increased aggregation compared to
Q40Bristol animals. Insets show polyQ40 aggregation in the head muscles. b The scheme for generation of the drxIR1;Q40 strain through rounds
of serial backcrossing/selection. RIL2 strain was backcrossed (BC) into the Q40Bristol strain 23 times. DR1350-derived variants (red) that are
retained through the crossing-selection scheme likely contribute to the RIL2 polyQ phenotype. c The drxIR1;Q40 animals exhibit a faster
accumulation of polyQ aggregates compared to Q40Bristol at all development stages, until both strains reach maximum at day 2 of adulthood.
L3, L4, YA, and D2 adult indicate third and fourth larval stage, young adult, and day 2 adult stage, respectively. Data are mean ± SD, 10 to 20
animals per data point. Data were analyzed by ANOVA followed by Bonferroni’s multiple comparisons test, ****P < 0.0001, ***P = 0.0004. Orange:
Q40Bristol background, red: drxIR1;Q40. Same color scheme is used in all figures. d Distribution of DR1350-derived SNPs and any de novo
mutations on chromosome I that distinguish drxIR1;Q40 from Q40Bristol and Hawaiian strains. Gray-shaded area to the left of unc-11 shows a
locus with over 3000 unique SNPs in drxIR1;Q40 strain
Alexander-Floyd et al. BMC Biology           (2020) 18:18 Page 3 of 20
suggesting that the two phenotypes result from either
linked or same natural variant(s). Age-matched drxIR1;
Q40 animals had a higher number of polyQ40 aggre-
gates than Q40Bristol until day 2 of adulthood, when
polyQ40 aggregation reached maximum in both strains
(Fig. 1c). drxIR1;Q40 animals also exhibited somewhat
decreased motility at day 1 of adulthood (Additional file:
Fig. S1A); however, we do not relate these observations
to aggregation since we have previously showed that nat-
ural variation can uncouple aggregation from its associ-
ated toxic effects [38]. Thus, natural variants present in
the wild isolate DR1350 can modify polyglutamine ag-
gregation when introgressed into the Bristol genetic
background.
Polyglutamine aggregation-modifying variants reside in a
large interval inherited from the DR1350 parent
In order to identify the causative variant(s) in the back-
crossed drxIR1;Q40 strain, we first used mapping strains
with visible mutations on each chromosome, and found
that increased aggregation segregated with the left arm
of chromosome I. This location was confirmed (de-
scribed further below) using a free duplication sDP2
[46], which covers the left arm of chromosome I through
dpy-5 (Additional file: Table S1). To precisely map the
variant(s), we performed genome sequencing of both the
drxIR1;Q40 and Q40Bristol strains and identified SNPs
present only in the former, using Galaxy CloudMap
pipeline described in [47]. We found that the left arm of
chromosome I in the backcrossed drxIR1;Q40 strain
contained an 1.43-Mb interval (ChrI:832,674-2,262,484),
with over 4000 SNPs. Because our previous data showed
that introgression of the Q40 transgene into the com-
monly used CB4856 (Hawaiian) strain did not result in
the same aggregation phenotypes as in the DR1350
background [38], we used the list of known Hawaiian
SNPs within the CloudMap pipeline [47] and subtracted
them from the remaining drxIR1;Q40 SNPs. The gen-
ome of the Hawaiian strain is known to be highly diver-
gent from the Bristol/N2 genome [45, 48]. After
subtraction, the interval still contained over 3000 SNPs
(Fig. 1d). We tested whether this interval was also
present in the remaining four high-aggregation RILs
from the original study, by following several SNPs within
the interval (Additional file: Fig. S1). We found that
three of the RILs indeed inherited the entire interval,
while the interval in the fourth one (RIL15) was shorter
on the right side, extending through SNP 6 at ChrI:1,850,
249 (WBVar00017051), but not through SNP 6b at ChrI:1,
972,719 (WBVar00017376) (Additional file: Fig. S1). Thus,
4 independent RILs with high polyQ aggregation pheno-
types, and the 23 times back-crossed drxIR1;Q40 strain
derived from another RIL (RIL2), all contained the paren-
tal interval ChrI:832,674-1,972,719 from the high-
aggregation DR1350;Q40 strain. To confirm, we used a
mutation in egl-30 gene located within this interval
(Additional file: Fig. S1). Consistent with a close genetic
linkage, we were unable to find any F2 progeny from 10
F1 heterozygotes from a cross between drxIR1;Q40 and
egl-30(n686) animals that showed both the RIL2-like
polyQ head aggregation phenotype and the egl phenotype
(> 1000 F2s). Furthermore, in subsequent genetic crosses
between drxIR1;Q40 and Q40Bristol animals, we observed
a complete correlation between F2 progeny inheriting 2
copies of this interval, as detected by following SNP 5
(WBVar00016276) (see the “Methods” section), and the
appearance of the 2 polyQ phenotypes (> 100 animals).
Together, these data indicate that ChrI:832,674-1,972,719
interval is responsible for increased polyQ aggregation
phenotypes.
The remaining part of chromosome I contained 68
additional SNPs relative to the Q40Bristol parental
strain, and all the other chromosomes accumulated less
than 200 unique SNPs each (Additional file: Fig. S2),
consistent with previous reports [49]. The large size of
the modifier interval was unexpected after 23 back-
crosses, suggesting that it may contain structural vari-
ants preventing recombination over this region.
Alternatively, this locus could contain more than one
SNP responsible for the phenotypes, perhaps distributed
over the interval. Of note, the known chromosome I
zeel-1/peel-1 incompatibility locus [50] was not respon-
sible for the retention of the modifier interval through
the backcrosses, as it lays outside the mapped interval
(Additional file: Fig. S1B), and does not contain
DR1350-derived SNPs in the drxIR1;Q40 strain.
Known regulators of proteostasis are not responsible for
increased polyQ aggregation in drxIR1 animals
Because the identified modifier locus contained a large
number of SNPs, we thought to narrow down the candi-
date pathway(s) in which the modifier gene(s) acted. We
first asked whether the variants in the drxIR1 locus were
increasing polyglutamine aggregation by affecting either
the protein homeostasis of the muscle cells, or the Q40::
YFP protein itself. We have previously tested and ex-
cluded the trivial explanation that the increased aggrega-
tion in our five RILs was due to the increased expression
of the Q40::YFP protein [38]. Nonetheless, we consid-
ered a possibility that drxIR1 locus could cause increased
activity of the unc-54 promoter that was used to drive
the polyglutamine transgene. To test this, we introduced
an integrated unc-54p::GFP::UNC-54 transgene [51] into
the drxIR1 background, in the absence of polyQ, and ex-
amined its expression. We found no differences in the
fluorescence levels, suggesting normal unc-54 promoter
activity (Fig. 2a). Since assembly of myofilaments is sen-
sitive to both the levels of UNC-54 myosin heavy chain
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protein and the activity of molecular chaperones, it pro-
vides an additional measure of the GFP::UNC-54 protein
levels and of the folding environment [52–54]. We found
normal striated pattern of GFP::UNC-54 protein in both
Bristol and drxIR1 genetic backgrounds (Fig. 2b).
Another reason for increased aggregation could be de-
creased protein turnover. To address this, we asked
whether basal autophagy or proteasome activity was re-
duced in the muscle cells of drxIR1 animals. Using a
well-characterized autophagy reporter ubiquitously ex-
pressing GFP::LGG-1 [55], GFP::LGG-1 puncta were
counted in muscle cells of wild-type and drxIR1 animals,
in the absence of Q40::YFP protein to avoid spectral
overlap. Consistent with previously published results, the
Fig. 2. Basal protein homeostasis of muscle cells is unaffected in animals carrying the drxIR1 interval. a Expression of GFP::UNC-54 fusion protein
from unc-54 promoter is similar between the Bristol and drxIR1 L4 animals. Data are mean ± SD of GFP fluorescence intensity, 16–20 muscle cells
per genotype, unpaired t test, two-tailed. b Myofilament assembly is normal in drxIR1 animals. Confocal images of muscle cells. Scale bar, 10 μm. c
Muscle cells have very few GFP::LGG-1-positive puncta (arrowheads) in both Bristol and drxIR1 L4 animals. One muscle quadrant is shown
between punctate lines. m, muscle; hyp, hypodermis. An increased number of GFP::LGG-1-positive puncta is seen in the hypodermis of drxIR1.
Scale bar is 10 μm. Right panel, quantification of GFP::LGG-1 puncta in the muscle cells. Data are mean ± SD, 30 to 40 cells (8 to 10 animals) per
genotype, unpaired t test, two-tailed; each symbol represents individual cell. d No difference in the average intensity of the proteasome reporter
fluorescence in Q40Bristol and drxIR1;Q40 animals. Data are mean ± SD, 4–5 animals, unpaired t test, two-tailed. e The increased aggregation
phenotype in animals carrying the drxIR1 interval does not depend on DAF-16 or HSF-1. Each symbol represents an individual animal, 15 mid-L4
animals per genotype. O/E, overexpression. Means ± SD are overlaid. Data were analyzed by ANOVA followed by Bonferroni’s multiple
comparisons test, ****P < 0.0001
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number of GFP-positive puncta in muscle cells of L4 an-
imals with the Bristol background was low [56, 57], and
we detected no difference in basal autophagy in the
muscle cells of drxIR1 animals (Fig. 2c), although the in-
creased number of puncta was noted in their lateral hy-
podermis. To test whether decreased proteasomal
activity could be responsible for increased aggregation
seen in the drxIR1;Q40 animals, we introduced a
muscle-specific UbG76V::Dendra2 reporter [58] into
Q40Bristol and drxIR1;Q40 animals, and measured its
fluorescence. We detected no increase in Dendra2 fluor-
escence in drxIR1 animals, indicating that there was no
decrease in proteasome activity (Fig. 2d). To confirm
that the reporter was sensitive to decreased proteasome
activity, we reduced expression of the rpn-6.1 subunit of
19S regulatory complex of the proteasome via RNAi [58]
and detected an increase in Dendra2 fluorescence (Add-
itional file: Fig. S3A). These data indicate that increased
polyglutamine aggregation in the muscle cells of drxIR1
animals is not due to the changes in protein degradation
or in polyQ protein levels.
Next, we tested two main transcriptional pathways
known to regulate cytosolic protein homeostasis—insu-
lin/IGF signaling and the heat-shock response. Increased
activity of DAF-16/FOXO, the transcription factor of the
insulin/IGF signaling pathway, is associated with im-
proved proteostasis and has been shown to affect poly-
glutamine aggregation [30, 36]. We found that neither
genetic inactivation of daf-16, using daf-16(mu86) muta-
tion [59], nor overexpression of active DAF-16::GFP pro-
tein [60] were able to revert the increased aggregation
seen in drxIR1;Q40 animals (Fig. 2e). HSF-1/HSF1 is the
heat-shock transcription factor that functions as a mas-
ter regulator of molecular chaperones, degradation ma-
chinery, and other proteostasis components in the
cytosol, and has also been shown to affect polyQ aggre-
gation in wild-type animals [36]. Similarly to DAF-16,
neither the hypomorphic hsf-1(sy441) allele, deficient in
the heat-shock response [61], nor HSF-1 overexpression
[62] were able to revert the increased aggregation caused
by drxIR1 background (Fig. 2e). Together, these data in-
dicate that the DR1350-derived variants in drxIR1 are
not likely to act by modifying the basal proteostasis of
the muscle cells of C. elegans.
Variants in the introgressed interval do not alter
biophysical properties of polyQ40 aggregates
Besides changes in the cellular proteostasis of muscle
cells, increased aggregation in drxIR1;Q40 animals could
reflect changes in the amyloid-like nature and/or bio-
physical properties of polyQ40 aggregates themselves.
PolyQ40 is known to form immobile aggregates that do
not recover after photobleaching and are resistant to
treatment with the detergent SDS [30, 63]. Thus, we
tested whether the presence of drxIR1 interval altered
these properties of polyQ40 aggregates. As expected,
photobleaching foci within Q40Bristol resulted in essen-
tially no recovery of fluorescence, while soluble Q40::
YFP protein rapidly recovered to pre-bleach levels
(Fig. 3a). We found no difference in recovery of Q40::
YFP foci between drxIR1;Q40 and Q40Bristol animals
(Fig. 3a), indicating similarly immobile aggregates. To
test for SDS resistance, we extracted aggregates from
Q40Bristol and drxIR1;Q40 animals and treated them
with 5% SDS at room temperature, as described in [39].
We found polyQ aggregates to be similarly SDS resistant
in both genetic backgrounds (Fig. 3b). To confirm that
our SDS treatment could dissociate non-amyloid protein
assemblies, we tested GFP::UNC-54 protein that forms
myofilaments (as shown in Fig. 2b). Filamentous GFP::
UNC-54 protein was efficiently dissociated by SDS treat-
ment in extracts from both Bristol and drxIR1 back-
grounds (Fig. 3b).
Recently discovered positive regulator of aggregation,
MOAG-4/SERF, which specifically distinguishes amyloid
and non-amyloid aggregation [64, 65], was shown to
affect Q40::YFP protein in C. elegans: decrease of moag-
4 expression via RNAi suppressed Q40 aggregation [65].
To test whether the variants in the drxIR1 background
act through MOAG-4, expression of moag-4 was
knocked down by RNAi in Q40Bristol and drxIR1;Q40
animals. moag-4 RNAi strongly decreased polyQ40 ag-
gregation in both backgrounds, confirming the amyloid-
like nature of aggregation in both (Fig. 3c (L4 animals)
and Additional file: Fig. S3B (young adults)). However,
drxIR1;Q40;moag-4(RNAi) animals retained higher ag-
gregation relative to Q40Bristol;moag-4(RNAi) animals
(Fig. 3c), as well as the increased susceptibility of the
head muscles (Additional file: Fig. S3B), arguing against
the drxIR1 interval variants acting through MOAG-4-
mediated mechanism. Together, our data suggest that
neither decrease in muscle proteostasis nor changes in
the aggregation pathway are responsible for the in-
creased aggregation in drxIR1;Q40 animals.
The increased aggregation is specific to polyglutamine
expansions
To determine whether the variants responsible for in-
creasing polyQ40 aggregation in drxIR1;Q40 animals
were acting generically on any amyloid aggregates, we
asked if they can modify an aggregation-prone Aβ pep-
tide. We chose the muscle-specific Aβ1-40::CFP trans-
gene [66] because it exhibits both soluble and
aggregated protein early in adulthood. We found that
introduction of the drxIR1 interval did not increase Aβ
aggregation (Fig. 3d). In contrast, when the drxIR1 locus
was introduced into another polyglutamine model,
Q35Bristol, we observed both the overall increase in
Alexander-Floyd et al. BMC Biology           (2020) 18:18 Page 6 of 20
polyQ35 aggregation and the increased susceptibility of
the head muscles (Fig. 3e).
These data indicate that the DR1350-derived vari-
ants in drxIR1 background act by a polyglutamine-
specific mechanism that is likely distinct from the
known aggregation-modifying mechanisms. In
addition, the effect on the Q35::YFP and Q40::YFP
but not on Aβ1-40::CFP transgenic proteins confirms
that the novel mechanism acts at the protein level,
rather than by modifying the transgene genomic
environment, since all three transgenes were made by
the same approach.
Increased polyQ40 aggregation in the body-wall muscle
cells and switch in susceptibility of the head muscles to
aggregation are caused by genetically separable
mechanisms
Since we were unable to narrow down the candidate
genes by identifying affected pathways, and our data
pointed to a potentially novel pathway, we turned to an
Fig. 3. Variants in drxIR1 interval do not alter the biophysical properties of polyQ aggregates. a FRAP analysis. The soluble Q40::YFP protein
recovered rapidly (triangles), while aggregated protein (circles) in both Q40Bristol and drxIR1;Q40 backgrounds does not recover. Data are
mean ± SD. b PolyQ40 aggregates in native extract from drxIR1;Q40 animals remain resistant to 5% SDS. Aggregated proteins fail to enter the
native gel, remaining in the wells (shown). Native extracts containing the fibrillar GFP::UNC-54 protein were used as controls. c The increased
aggregation phenotype in animals carrying the drxlR1 interval does not depend on the amyloid-specific modifier moag-4 (mid-L4 animals; YA
animals are shown in Suppl. Fig. 3B). Data are mean ± SD, three independent experiments. Thirty-eight to 46 animals per condition. Data were
analyzed by ANOVA followed by Bonferroni’s multiple comparisons test, ****P < 0.0001. d Aggregation of a different amyloid protein, Aβ1-40::CFP,
in unaffected by the drxlR1 locus. Shown are confocal stacks, arrows point to aggregates, and asterisks indicate Aβ1-40::CFP accumulating in the
nuclei of the muscle cells. Scale bar, 10 μm. e The shorter polyQ expansion (Q35::YFP) exhibits both the increased susceptibility of the head
muscle cells and the accelerated overall aggregation in animals carrying the drxlR1 interval. Shown are stereo micrographs; arrows point to some
of the aggregates. D1Ad, day 1 adults
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unbiased investigation of genes in the interval. As we
previously reported [38], the increased susceptibility of
the head muscles to aggregation (RIL2-like phenotype,
measured as the ratio of head to body aggregation) be-
haves as a recessive trait (Additional file: Table S1, top
row), and is fully suppressed in drxIR1 heterozygous
(drxIR1/+;Q40) animals. Thus, we asked whether it was
caused by a loss of function of a gene or genes in the
interval, by testing whether it can be rescued in the
drxIR1 homozygotes by introducing a wild-type copy of
the interval. We used a free duplication sDp2 that covers
the left arm of chromosome I, through dpy-5 gene in the
center of the chromosome [46]. Introduction of sDP2
into animals homozygous for the drxIR1 interval and for
the known loss-of-function dpy-5(e61) allele suppressed
both the dpy and the RIL2-like head phenotypes to the
same extent (Additional file: Table S2, second row), indi-
cating that the switch in head-muscle susceptibility
phenotype in drxIR1 animals is caused by a loss-of-
function variant(s), and therefore can potentially be
identified by RNAi approach in Q40Bristol animals.
In contrast, the second polyQ phenotype, the in-
creased overall aggregation (as scored in the body-wall
muscles alone, excluding the head muscles), was not
suppressed in animals heterozygous for the drxIR1 inter-
val (Fig. 4a). Moreover, introduction of the sDP2 dupli-
cation, carrying the wild-type (Bristol) copy of this
interval, into either Q40Bristol or drxIR1;Q40 animals
resulted in sharply increased aggregation of polyQ40 in
the body-wall muscles, relative to the corresponding
strains without the duplication (Fig. 4a). This suggests
that the phenotype of increased aggregation in the body-
wall muscles depends on the dosage of a gene or genes
within the boundaries of the modifier interval, and that
in drxIR1;Q40 animals, this gene carries hypermorphic
variant(s), mimicking increased gene dosage. Thus, the
candidate gene may be identified by RNAi approach in
drxIR1;Q40 animals.
Autophagy-related gene 5 (ATG-5) is responsible for
increased aggregation
To decrease the number of genes that were to be tested
by RNAi, we were able to further narrow the large
drxIR1 interval (Additional file: Fig. S1B, C) to approxi-
mately 326 Kb (ChrI:1,647,221-1,972,719) by additionally
backcrossing the drxIR1;Q40 animals and using the
SNPs in the interval to detect recombination. The
smaller 326 Kb interval contained 57 total genes includ-
ing 25 candidate protein-coding genes with potentially
functionally significant SNPs (based on SnpEff annota-
tions [67], see the “Methods” section), with 24 candidate
genes remaining after exclusion of egl-30 (Additional file:
Table S2 and Additional file: Data File 1). Each of the
candidate genes was knocked down by feeding RNAi in
both Q40Bristol and drxIR1;Q40 animals, followed by
quantification of polyQ aggregation.
None of the RNAi clones affected the increased suscepti-
bility of the head muscles to polyQ aggregation (measured
as a ratio of head to body aggregation) in either back-
ground. This may potentially indicate that more than one
gene in the interval was responsible for the switch in the
head muscle susceptibility, or that it depends on SNPs in
non-coding RNAs, intergenic regions, or genes with SNPs
that were not selected as potentially functionally significant;
alternatively, this failure could be due to an inefficient
knockdown. On the other hand, RNAi of several genes
modified the second phenotype—the overall aggregation of
polyQ40 in the body-wall muscle cells. Decreasing expres-
sion of two genes, Y71G12B.23 and C53H9.3, caused an in-
crease in the number of aggregates in the Q40Bristol
animals, with no change in the drxIR1;Q40 animals, while
knocking down expression of atg-5 caused a large decrease
in aggregation in the drxIR1;Q40 strain, with no effect in
the Q40Bristol background (Fig. 4b). Because reversal of in-
creased aggregation specifically in drxIR1;Q40 animals by
RNAi is consistent with our genetic analysis for this pheno-
type in Fig. 4a, which suggested that the causative variant in
drxIR1 background is hypermorphic, this points to atg-5 as
a candidate gene. Based on the genome sequencing, atg-5
gene in drxIR1;Q40 strain contains unique SNPs in its 3′
UTR (Additional file: Data File 1).
The hypermorphic effect of SNPs localized in regula-
tory regions can be caused by increased expression of
the affected gene or protein. qPCR data revealed no dif-
ferences in atg-5 transcript levels in drxIR1 or drxIR1;
Q40 animals compared to their respective Bristol strains
(Fig. 4c). Thus, we asked whether decreasing the protein
expression via a targeted deletion of atg-5 could reverse
the increased polyQ aggregation in drxIR1;Q40 animals,
as expected if the variants were hypermorphic. We used
atg-5(bp484) allele, which has a mutation in a splice
donor site of exon 1 disrupting the protein’s expression
or function [68, 69]. We found that unlike animals that
carried one DR1350-derived and one Bristol copy of the
interval (drxIR1/+;Q40), which exhibit increased aggre-
gation (Fig. 4a), drxIR1 heterozygous animals carrying
the atg-5 mutation in the Bristol-derived copy (drxIR1/
atg-5;Q40) completely lost the increased aggregation
phenotype (Fig. 4d). These data suggest that increased
levels of ATG-5 protein cause increased polyglutamine
aggregation in the body-wall muscle cells.
Activation of autophagy has divergent effects on polyQ
aggregation in different tissues
ATG-5 is an orthologue of the autophagic budding yeast
protein ATG5 and of human ATG5. ATG-5 contributes to
the initiation of autophagy by forming a complex with
LGG-3/ATG12 and ATG-16/ATG16L1, which is recruited
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to the membrane of the elongating phagophore [70–72],
and is required for the lipidation of LGG-1/LC3. Thus, up-
regulation or activation of ATG-5 by the hypermorphic al-
lele could cause either overactivation or an imbalance in
autophagy. Interestingly, ATG5 in mammalian cells can
also contribute to the progression of apoptosis, independ-
ent of its role in autophagy [73].
Although under basal conditions we saw no increase
in the number of GFP::LGG-1 puncta in the muscle cells
of drxIR1 animals (Fig. 2a), we did observe more puncta
in the hypodermal cells, where autophagy is most readily
induced in long-lived mutants [74]. Thus, we asked
whether induction of autophagy the muscle cells was dif-
ferent in drxIR1 and wild-type (Bristol) animals under
activation conditions. We used an autophagy inducer
drug, ABT-737, that acts as a BH3-mimetic, inhibiting
the antagonistic effects of Bcl-2 (CED-9 in worms) on
Beclin-1 (BEC-1) and thus relieving inhibition of
Fig. 4. Hypermorphic variants in the autophagy gene atg-5 are responsible for the increased polyQ aggregation in the body-wall muscles. a
PolyQ aggregation in the body-wall muscles is sensitive to the dosage of the drxlR1 interval, with DR1350-derived interval acting as a
hypermorph relative to the Bristol-derived interval. Each symbol represents an individual mid-L4 animal; overlaid are means ± SD. Schematic
under the graph represents the genetic composition of chromosome I: Bristol background (orange bar), DR1350-derived drxlR1 interval (red
arrow), and the free duplication sDp2 (green bar). b RNAi of three candidate genes affects polyQ40 aggregation. atg-5 RNAi suppresses the
increased polyQ aggregation in the muscle cells of drxlR1 but not in Q40Bristol animals. RNAi against YFP downregulates expression of Q40::YFP
protein. Data are mean ± SD, 3 independent experiments, 9 to 15 animals per experiment per genotype. Data were analyzed by ANOVA followed
by Bonferroni’s multiple comparisons test, ****P < 0.0001, **P = 0.0029, *P = 0.0125. c Relative expression of atg-5 mRNA is unaffected by the
DR1350-derived drxIR1 interval. Three independent experiments, statistics as in b. d atg-5(bp484) loss-of-function allele reverses increased
aggregation caused by one copy of the DR1350-derived drxIR1 interval. Schematic under the graph as in a, star: atg-5 mutation. Animals were
scored at mid-L4 as in a, compare drxIR1/+;Q40 animals (red/orange symbols) in a with drxIR1/atg-5;Q40 animals (red/gray symbols) in d. Gray
symbols represent animals that were assumed (but not confirmed) to be heterozygous for the drxIR1 interval, because they did not show the
RIL2-like phenotype head muscle phenotype and because atg-5/atg-5 animals exhibit strong developmental delay. Heterozygosity of drxIR1/atg-
5;Q40 animals (red/gray symbols) was confirmed by singling them out and scoring segregation of the RIL2-like phenotype among their progeny.
Each symbol represents an individual animals, overlaid are means ± SD
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autophagy [75]. Treatment with 10 μM of ABT-737 in-
deed induced GFP::LGG-1 puncta in the muscle cells of
the wild-type (Bristol) animals (Fig. 5a). Surprisingly, an-
imals carrying the drxIR1 interval exhibited an increase
in punctate appearance of GFP::LGG-1 protein in the
body-wall muscle cells already in response to the DMSO
control. Although not previously reported to activate au-
tophagy, low concentrations of DMSO have been re-
ported to extend the lifespan of C. elegans and decrease
the paralysis associated with Aβ1-42 aggregation, when
grown in liquid [78, 79]. Importantly, ABT-737 resulted
in a larger increase in GFP-positive puncta in drxIR1;
GFP::LGG-1 animals compared to the Bristol back-
ground (Fig. 5a), indicating that drxIR1 interval increases
accumulation of LGG-1/LC31-positive autophagosome
structures in response to an activating treatment.
The larger increase in LGG-1 puncta in drxIR1;GFP::
LGG-1 animals could indicate that atg-5 hypermorphic
allele causes either a stronger activation of autophagy or
a slower lysosomal degradation. Because autophagy is
known to promote clearance of polyglutamine aggre-
gates [80], the increased aggregation in drxIR1 back-
ground appeared consistent with slower degradation,
while activation of autophagy would have been expected
to decrease aggregation [81]. To confirm this, we asked
whether activation of autophagy with ABT-737 indeed
decreased polyQ aggregation in the wild-type (Bristol)
background. Surprisingly, treatment of Q40Bristol ani-
mals with this autophagy activator resulted in a large in-
crease, rather than decrease, of polyQ40 aggregation in
the body-wall muscles, with ABT-737-treated animals
exhibiting a 44% increase in the number of aggregates
(Fig. 5b). These data suggest that counter to expecta-
tions, activation of autophagy may enhance polygluta-
mine aggregation. We did not detect a further increase
in aggregation in drxIR1 background, since the drug
treatment protocol dictated scoring aggregates in young
adult animals (see the “Methods” section), when aggre-
gation in drxIR1;Q40 is already close to maximal.
Because this effect of autophagy was unexpected, and
because drug treatment may not be reliable in C. ele-
gans, we tested two different genetic approaches known
to activate autophagy to confirm these findings. Each of
the two approaches activates autophagy via a mechanism
distinct from that of ABT-737. First common approach
is inactivation of mTOR [82]. In C. elegans, inactivation
of LET-363/mTOR indeed activates autophagy, as shown
by increase in GFP::LGG-1 puncta [83]. However, inacti-
vation of LET-363 also causes larval arrest [84], which it-
self will affect polyQ aggregation. To overcome this, we
targeted mTOR interacting protein MLST-8/mLST8,
which is required for the kinase activity of mTOR [85],
but can be downregulated in C. elegans without causing
larval arrest [86]. RNAi knockdown of mlst-8 resulted in
a 1.6-fold increase in polyQ40 aggregation in Q40Bristol
animals (Fig. 5c, late-L4). Similar to the results of the
drug treatment, mlst-8 RNAi had no significant effect in
drxIR1;Q40 animals. We asked whether the apparent
lack of effect on the drxIR1;Q40 animals was indeed due
to the already high aggregate numbers at this develop-
mental stage, by repeating the RNAi in younger animals,
and observed an even stronger, 3-fold, increase in
polyQ40 aggregation in Q40Bristol animals, and a 1.5-
fold increase in drxIR1;Q40 animals (Fig. 5c, mid-L4).
As a second genetic approach, we tested the effect of
decreased activity of insulin/IGF-like signaling pathway,
since reduction of function of the sole C. elegans ortho-
logue of insulin/IGF receptor, DAF-2, is known to cause
activation of autophagy, including in the body-wall
muscle cells [57, 87]. Introduction of the hypomorphic
daf-2(e1370) allele caused a 5.1-fold increase in aggre-
gates in the Q40Bristol background, and 2.3-fold further
increase in drxIR1;Q40 animals (Fig. 5d). The increase in
polyQ aggregation in daf-2(e1370) background is con-
sistent with previous reports [88]. Together, these
pharmacological, RNAi, and genetic data suggest that
aggregation of polyQ40 in the body-wall muscle cells is
paradoxically increased by activation of autophagy.
Previous studies indicate that autophagy levels, both ba-
sally and in response to a trigger, can be different in differ-
ent C. elegans and mammalian tissues [56, 89]. Intriguingly,
in these reports, certain muscle groups in the mouse [89]
and body-wall muscle cells in C. elegans [56, 57] exhibited
lower basal autophagy compared to other tissues. Thus, we
asked whether activation of autophagy may have a different
effect on polyQ aggregation in muscles than in a different
tissue. In addition to the muscle-expressed polyQs, the
neuronal and intestinal fluorescent polyQ models have
been established in C. elegans [76, 90]. We applied the same
mlst-8 RNAi approach to the intestinal model and scored
polyQ aggregation. Unlike in the muscle-expressing polyQ
model, activation of autophagy via RNAi knockdown of
mlst-8 resulted in a large (3.5-fold) decrease in the percent-
age of animals exhibiting polyglutamine aggregation in in-
testine (Fig. 5e). Finally, we tested the effect of autophagy
activation on polyglutamine aggregation in C. elegans neu-
rons. The integrated polyQ67 expansions expressed at low
levels from the pan-neuronal F25B3.3 promoter (Q67n::
CFP) presents with both soluble protein and aggregates in
day 1 adult animals. Because neurons in C. elegans are re-
fractory to feeding RNAi, we introduced the drxIR1 locus
into Q67n::CFP animals, and scored the number of ag-
gregates in the neurites of head neurons (Additional
file: Fig. S4). Strikingly, we found that like in the intes-
tine but unlike in the muscle cells, introduction of the
drxIR1 locus into the neuronal polyQ model signifi-
cantly decreased the number of CFP-positive aggregates
in the neurites (Fig. 5f and Additional file: Fig. S4). Of
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note, protein aggregation-induced trafficking defects in
neurites are common in neurodegeneration, and au-
tophagy in neurons is known to be regulated in a
compartment-specific manner [91].
Together, these data show that depending on the
tissue, activation of autophagy can either clear
polyglutamine aggregates or increase their
accumulation.
Fig. 5. Activation of autophagy has divergent effects on polyQ40 aggregate clearance in different tissues. a Animals carrying the drxIR1 interval
accumulate more GFP::LGG-1-positive puncta (arrowheads) in the body-wall muscle cells upon treatment with autophagy-activating drug ABT-
737. Animals were treated with 0.1% DMSO (vehicle control) or 10 μM ABT-737 for 24 h. Shown are confocal projections; one muscle quadrant
(m) is indicated between punctate lines. Scale bar, 10 μm. b Autophagy-activating drug ABT-737 increases polyQ40 aggregation in the body-wall
muscle cells in the wild-type background (Q40Bristol). Aggregation was scored in adult animals, 1 day post-L4 (see the “Methods” section).
Aggregation in the drxIR1;Q40 animals is already at maximum under these conditions. Each symbol indicates an individual animal; overlaid are
means ± SD. Data were analyzed by ANOVA followed by Bonferroni’s multiple comparisons test, ***P = 0.0006. c Activation of autophagy with
mlst-8 RNAi increases aggregation in the body-wall muscles of Q40Bristol mid- or late-L4 animals, and of drxIR1;Q40 mid-L4 animals. Data are
mean ± SD, 3 independent experiments, 9 to 13 animals per experiment per treatment. Control RNAi was mec-4. Data were analyzed by ANOVA
followed by Bonferroni’s multiple comparisons test, ***P = 0.0007, **P = 0.0082. d Introduction of the daf-2(e1370) allele increases polyQ40 aggregation
in the body-wall muscles in both Q40Bristol and drxIR1;Q40 animals. Aggregation was scored at mid-L4. Each symbol indicates an individual animal;
overlaid are means ± SD. Colors as in b. Data were analyzed by ANOVA with Bonferroni’s multiple comparisons test, ****P < 0.0001. e Activation of
autophagy with mlst-8 RNAi strongly suppresses polyQ aggregation in the intestinal cells. Percent of animals with Q44::YFP aggregates in the intestine
of day 4 adult were scored, as in refs. [76, 77], for each indicated RNAi treatment. Control RNAi was mec-4. Data are mean ± SD. Data were analyzed by
ANOVA followed by Bonferroni’s multiple comparisons test, ***P = 0.0003. f The drxIR1 interval decreases accumulation of polyQ67 aggregates in the
neurites of head neurons. Aggregation was scored in day 1 adults over the dendritic area in the head, as shown in Additional file 4: Figure S4. Each
symbol indicates an individual animal; overlaid are means ± SD. Data were analyzed by an unpaired t test, two-tailed, *P = 0.0332
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Discussion
Using natural genetic variation, we identified an unex-
pected divergence in how activation of autophagy in dif-
ferent tissues impacts the behavior of aggregation-prone
polyglutamine expansions. It is broadly appreciated that
autophagy can be both protective and detrimental to
cells and organisms [92]. For example, ER stress-induced
autophagy is protective in cancer cells but contributes to
apoptosis in non-transformed cells [93], while
starvation-triggered autophagy in C. elegans pharyngeal
muscle can switch from protective to pro-death, depend-
ing on its level of activation [55]. However, with respect
to clearance of misfolded aggregated proteins, activation
of autophagy is generally considered to be a positive,
protective response [94, 95]. Therefore, activation of au-
tophagy has been thought of as a nearly universal thera-
peutic approach to neurodegenerative diseases caused by
protein aggregation [96]. The divergence in how polyQ
expansions in neuronal, intestinal, and muscle cells re-
spond to activation of autophagy suggests that interplay
between autophagy and protein aggregation depends on
the cellular context. We find that both the natural vari-
ants in atg-5, and the more traditional genetic and
pharmacological ways of activating autophagy independ-
ent of atg-5, increased rather than decreased polyQ ag-
gregation in the muscle cells of C. elegans. This
represents a striking departure from the current para-
digm. On the other hand, polyQ aggregation in neuronal
and intestinal cells, as expected, was decreased by the
same treatment. Considering the significant involvement
of skeletal muscle in HD and other polyglutamine dis-
eases, including the induction of the muscle catabolic
phenotype and muscle wasting [97–101], a more nu-
anced understanding of integration of autophagy with
cellular physiology is needed.
The use of natural variation was instrumental in unco-
vering this unexpected cell-specific effect of autophagy
on protein aggregation. The DR1350-derived variants
that we identified as being responsible for the increased
aggregation of polyQ40 in the muscle cells are in the
regulatory 3′UTR region of the atg-5 gene. Although 3′
UTR variants could affect activity in some proteins, for
example, by affecting localization of mRNA and thus its
local translation, our genetic analysis points to the gain
of expression as the mechanism of atg-5 variants. Based
on the ability of one additional copy of the wild-type,
Bristol-derived atg-5 to mimic the effect of these natural
variants (Fig. 4a), and because deletion of one copy of
atg-5 reverses the effect of the DR1350-derived variants
in the remaining copy (Fig. 4d), we estimate that the var-
iants increase the expression of ATG-5 protein by less
than twofold. Strikingly, introduction of one additional
Bristol-derived copy of atg-5 into the animals already
carrying two DR1350-derived hypermorphic alleles
increases the polyQ aggregation even further, to about
sixfold above normal. This indicates a quantitative rela-
tionship between the levels of ATG-5 protein and in-
creased polyQ aggregation in the muscle. Although we
are currently unable to directly modulate autophagy in
C. elegans in a graded manner, the ability of three dis-
tinct methods of activating autophagy to mimic the ef-
fect of the variants argues that the increase in ATG-5
affects the polyQ aggregation by increasing autophagy,
rather than for example by causing stoichiometric imbal-
ance and autophagy inhibition [81], or coupling to apop-
tosis pathway [73]. The precise mechanistic basis of this
quantitative relationship will need to be investigated
further.
Our approach in identifying the modifier variants was
different from the traditional QTL mapping and was
modeled on the EMS-density mapping method for mu-
tation identification [102]. We consider that the serial
backcrossing/selection scheme we used prior to whole
genome sequencing provides a generalizable approach to
mapping modifier variants in C. elegans, as it allows for
rapid enrichment of causative variants even from a sin-
gle available modifier background. This method also
simultaneously tests whether putative modifiers work in
different genetic backgrounds. Finally, because multiple
pathways can impinge on protein homeostasis, and in
addition, weakly-destabilizing coding polymorphisms
across genome can have strong effects on protein aggre-
gation or toxicity [37], each modifier background may
contain multiple loci contributing a combined effect.
The serial backcrossing/selection scheme tolerates
selecting of only a small number of recombinant animals
at each backcross, or even a singular animal exhibiting
the desired phenotype, and thus may be preferable for
such multi-loci modifiers.
One important aspect of our findings is the cryptic na-
ture of the modifier variants in atg-5. Cryptic variation
typically does not cause phenotypic changes on its own,
but becomes phenotypically “exposed” when challenged
with a stressful environment, thus contributing to dis-
ease susceptibility [103–105]. Polyglutamine expansions
may mimic cellular stress, for example, by destabilizing
the folding environment [37] or disrupting transcrip-
tional control [106]. Indeed, the atg-5 variants identified
here as modifiers are derived from a phenotypically nor-
mal wild strain DR1350, and we did not detect signifi-
cant alterations in the basal autophagy in the muscles of
drxIR1 animals, until they were challenged with the
aggregation-prone polyQ40, or with autophagy-
activating drug ABT-737.
In addition to being exposed by stress, the phenotypic
expression of cryptic modifier variants may reflect their
more direct interactions with the disease-causing muta-
tion. For example, in humans, analysis of HD modifier
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loci on chromosomes 8 and 15 showed that these vari-
ants influence certain clinical readouts in subjects with
expanded polyQ tracts, prior to the appearance of dis-
ease symptoms, while they have no major effects in con-
trol individuals without expansions [18]. The suspected
culprit for the modifying effect of the chromosome 15
locus, the DNA endo/exonuclease FAN1, may be chan-
ging the disease phenotypes or age of onset by directly
affecting the stability of the polyQ-encoding repeat in
somatic tissues [18, 107]. Interestingly, that study also
suggested that modifiers could have distinct effects in
different cell populations.
In our study, the cryptic nature of the atg-5 variants
allowed detection of the unusual tissue dependence of
the relationship between autophagy and aggregation, be-
cause stronger variants which ectopically activate au-
tophagy already under basal conditions often have
additional strong phenotypes potentially masking
changes in polyQ aggregation. For example, loss of func-
tion of C. elegans mTOR leads to larval arrest [84], while
hypomorphic mutations in insulin/IGF signaling path-
way, in addition to activating autophagy, trigger numer-
ous other developmental, stress responsive, and
metabolic pathways [108–110]; both can thus have their
own effects on the aggregation-prone protein. Even non-
genetic means such as activation of autophagy by nutri-
ent deprivation are accompanied by the metabolic and
protein expression changes [111] that can mask the
more specific effect on the polyQ behavior. Natural vari-
ation may thus indeed identify the candidate modifier
pathways and mechanistic relationships in aggregation
diseases that are distinct from those identified by the
traditional approaches.
The reasons the muscle cells are differentially sensitive
to autophagy with respect to protein aggregation, or why
this is not true for other aggregation-prone proteins, are
not yet known. The selectivity towards the polygluta-
mine expansions would argue against a global dysregula-
tion of protein homeostasis in the muscle cells of
drxIR1animals, which is supported by our data. It is pos-
sible, however, that ectopic activation of autophagy dis-
rupts select proteostasis processes that only impinge on
the polyQ aggregation or clearance in these cells. An-
other possibility is that autophagic degradation of polyQ
expansions requires a specific “signal” or adaptor, which
may be competed away during general increase in au-
tophagy in the muscle cells, but remains sufficient in in-
testine or neurons. The polyQ-expanded huntingtin
protein (Htt) indeed requires specific adaptors, such as
Tollip, to be cleared by autophagy [112], although
whether this is also true for polyQ expansions outside
the Htt context is not clear. Yet another possibility is
that polyQ expansions themselves interfere with autoph-
agy. For example, polyQ-expanded Htt have been
suggested to interfere with the delivery of cargoes to au-
tophagic vacuoles [113], and shown to co-aggregate with
the autophagy adaptor Tollip, potentially disrupting
other functions of this multi-tasking protein [112]. If so,
the low basal levels of autophagy may render the pro-
teostasis of the muscle cells to be selectively sensitive to
the polyQ expansions.
Muscle cells may also have a different regulation of or
dependence on autophagy, because autophagy of the
muscle is an adaptive response of many metazoans to
starvation [114]. While basal autophagy is important for
muscle maintenance, its over-activation can lead to
muscle atrophy [115–117]. Indeed, in C. elegans, body-
wall muscles in young animals have low basal levels of
autophagy relative to other tissues [56, 57], while in
mice, the slow-twitching (soleus) muscles exhibited little
induction of autophagy after 24 h of starvation, as de-
fined by the autophagosome counts, distinct from the
fast-twitching (extensor digitorum longus) muscles that
had significant induction [89]. Moreover, the distribu-
tion of autophagosomes was different between the fast-
and slow-twitching muscle types, supporting the idea of
differential autophagy regulation in different cells or
tissues.
In addition to the traditional mouse models, the genetic
model systems such as worm, fly, and yeast, in which nat-
ural variation can be readily combined with modeling the
gain-of-function disease mutations by transgenesis, offer
new opportunities to identify the cryptic modifier path-
ways for neurodegenerative and protein aggregation dis-
eases [10, 118–122]. Examples of this approach include a
study with Drosophila Genetic Reference Panel [123] that
uncovered an unexpected role of heparin sulfate protein
modifications in modifying the toxic effects of the mis-
folded mutant of human insulin, a cause of permanent
neonatal diabetes [124], and a recent study in C. elegans
that showed that the ability of α-synuclein to cause tran-
scriptional and phenotypic changes is substantially modi-
fied by the genetic background [40]. The important
feature of the cryptic modifier pathways that can be iden-
tified by these approaches is that they harbor natural vari-
ants shaped by selection, and thus will pinpoint the
naturally plastic potential genes and networks [14], amen-
able to pharmacological manipulation without negative ef-
fects on the organism.
Conclusion
Our work identifies a divergence in the ability of autoph-
agy to clear aggregates in different tissues. As activation
of autophagy is a promising therapeutic strategy for pro-
tein aggregation diseases, the vulnerability of muscle
cells in our study highlights the need for a more nu-
anced understanding of how autophagy integrates with
cellular physiology.
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Importantly, the finding that dramatic differences in
polyglutamine aggregation can be caused by physiological-
level differences in the autophagic response, encoded in
wild-type genomes, supports the use of natural genetic
variation in model organisms to interrogate pathways that
confer protection or susceptibility in protein aggregation
diseases.
Methods
Nematode strains and growth conditions
Nematodes were grown at 20 °C on nematode growth
medium (NGM) plates, seeded with E. coli OP50 [125].
Animals were synchronized by picking gastrula stage
embryos onto fresh plates, unless otherwise noted.
The following stains were obtained from Caenorhabdi-
tis Genetics Center (CGC): AM141 [rmIs333(punc-54::
Q40::YFP)], AM140 [rmIs132(punc-54::Q35::YFP) I],
CF1038 [daf-16(mu86) I], TJ356 [zIs356(pdaf-16::daf-
16a/b::GFP;pRF4(rol-6(su1006)) IV], PS3551 [hsf-
1(sy441) I], DA2123 [adIs2122(plgg-1::GFP::lgg-1 + rol-
6(su1006))], KR1108 [unc-11(e47) dpy-5(e61) I], KR292
[him-1(h55) dpy-5(e61) unc-13(e450) I; sDp2 (I;f)],
MT1434 [egl-30(n686) I], CB1370 [daf-2(e1370) III], and
AM44 [rmIs190(pF25B3.3::Q67::CFP)]. TGF205 [xzEx3(-
punc-54::UbG76V::Dendra2)] was made by crossing out
glp-1(e2141) from AGD1033.
The AS408 [punc-54::GFP::UNC-54], AM583 [rmIs249(-
plet-858::hsf-1;pmyo-2::GFP)], AM738 [rmIs297(pvha-6::
Q44::YFP;rol-6(su1006))], and AM930 [rmIs335(punc-54::
Aβ (1-40)::CFP)] strains were kindly provided by the Mor-
imoto lab, and the HZ1732 [atg-5(bp484) I;him-5] strain
by the Colón-Ramos lab. The Q40DR1350 and recombin-
ant inbred lines (RILs) 2, 12, 12(2), and 15 were described
in [38].
The drxIR1(I, DR1350>Bristol) locus and/or the Q40
locus was introduced by genetic crosses into the following
strains: TGF134 [drxIR1;rmIs333(punc-54::Q40::YFP)],
TGF130 [drxIR1;punc-54::GFP::UNC-54], TGF353 [drxIR1;
adIs2122(plgg-1::GFP::lgg-1 + rol-6(su1006))], TGF208 [xzE
x3(punc-54::UbG76V::Dendra2);rmIs333(punc-54::Q40::YFP
)], TGF207 [drxIR1;xzEx3(punc-54::UbG76V::Dendra2);rmI
s333(punc-54::Q40::YFP)], TGF088 [daf-16(mu86) I; rmIs





187 [hsf-1(sy441) I;rmIs333(punc-54::Q40::YFP)], TGF170
[drxIR1;hsf-1(sy441) I;rmIs333(punc-54::Q40::YFP)], TGF
036 [rmIs249(plet-858::hsf-1;pmyo-2::GFP);rmIs333(punc-
54::Q40::YFP)], TGF189 [drxIR1; rmIs249(plet-858::hsf-1;
pmyo-2::GFP);rmIs333(punc-54::Q40::YFP)], TGF203 [drxIR
1;rmIs335(punc-54::Aβ (1-40)::CFP)], TGF342 [drxIR1;
rmIs132(punc-54::Q35::YFP) I], TGF261 [rmIs333(punc-54::
Q40::YFP);him-1(h55) dpy-5(e61) unc-13(e450) I; sDp2 (I;
f)], TGF275 [drxIR1;rmIs333(punc-54::Q40::YFP);him-
1(h55) dpy-5(e61) unc-13(e450) I; sDp2 (I;f)], TGF089 [daf-
2(e1370) III;rmIs333(punc-54::Q40::YFP)], and TGF127
[drxIR1;daf-2(e1370) III;rmIs333(punc-54::Q40::YFP)].
The drxIR1;Q40 strain was made by the following
scheme: Q40Bristol males were mated to RIL2 hermaph-
rodites, and 5–10 F1 hermaphrodite progeny, identified
by the lack of RIL2-like increased head aggregation
phenotype, were picked onto fresh plates. F2 generation
was examined for the expected 1:3 segregation of the in-
creased head aggregation phenotype, and 7–10 F2 her-
maphrodites with this phenotype were further mated
with Q40Bristol males. This mating-selection cycle was
repeated 23 times. The resulting strain was named
drxIR1;Q40.
The introduction of drxIR1 locus by genetic crosses
was confirmed by detecting the presence of the SNP 5
(WBVar00016276) (Additional file: Fig. S1C): a 743-bp
fragment containing the variant was amplified using the
drxIR1 primers (Additional file: Table S3), at an anneal-
ing temperature of 60 °C, to produce an amplicon of
743 bp, and the PCR product was digested with SalI. The
SalI site is present in the Bristol background, producing
432 bp and 311 bp products after the digest, but is ab-
sent in the DR1350 background.
Genome sequencing
The 23× backcrossed RIL2 strain, renamed as drxIR1;
Q40, and the Q40Bristol stock that was used as the par-
ental strain during backcrossing procedure were col-
lected for sequencing within 2–3 generations after the
last backcross. Strains were also cryopreserved at this
time. A total of 20–30 animals of each strain were
allowed to propagate on several 10-cm plates seeded
with OP50 bacteria. Upon depletion of the bacteria, ani-
mals were collected, washed, and flash frozen for gen-
omic DNA extraction. Genomic DNA from drxIR1;Q40
and Q40Bristol frozen pellets was extracted using phe-
nol:chloroform (Sigma, USA). DNA was sequenced using
the NextSeq 500 System (Illumina, USA) at the Wistar
Institute (Philadelphia, PA, USA). Unpaired short reads
were analyzed using the Galaxy [126] CloudMap pipe-
line, as described in [47], against WS220 genome assem-
bly. Variants identified in the genome of Q40Bristol
strain, which was used for serial backcrossing of RIL2 to
generate the drxIR1;Q40 strain, were subtracted from
the drxIR1;Q40 SNPs. Because Hawaiian background did
not previously cause increased polyQ aggregation [38],
we also subtracted the known Hawaiian variants, using
the Hawaiian SNP file within the CloudMap pipeline.
This likely did not remove all the variants that over-
lapped between the Hawaiian and drxIR1;Q40 back-
ground, as the file did not contain the additional
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variants identified in ref. [48]. Finally, the CloudMap
SnpEff tool was utilized to annotate the resulting genetic
variants and predict their functional effects on genes and
proteins [67]. SNPs with the following annotations were
considered as potentially functionally significant: non-
synonymous coding, start gained or lost, stop gained or
lost, splice site donor/acceptor, frameshift, and 5′ or 3′
UTR.
Quantification of polyQ40 aggregation
Aggregation was scored by counting fluorescent foci in
images collected from animals immobilized with 20mM
NaN3. For aggregation in the muscle cells, images were
obtained using a Leica M205FA stereoscope with a digital
camera (Hamamatsu Orca R2). For synchronization, 15–
20 well-fed L4 animals from non-crowded plates were
transferred to new plates, gastrula stage embryos were
picked 2–3 days later, and hatched animals were allowed
to develop for specified time or to specified developmental
stage. Aggregation was scored in late-L4 animals, unless
otherwise indicated. The developmental larval stage was
confirmed based on the germline development, or by days
since L4 (for older adults). For data expressed as means,
the number of animals for each data point is indicated in
the figure legends.
For aggregation in neurons, images were obtained by
confocal microscopy, as described below. Confocal
stacks were collapsed as maximum-intensity projections
in ImageJ [127], and the number of aggregates was
counted in the dendritic area of animal’s head, as shown
in Additional file: Fig. S4. This area contains mainly den-
drites of sensory neurons, with some interneuron pro-
cesses and few cell bodies and/or neurites of other types
of neurons (https://www.wormatlas.org/neuronsandcir
cuits.html). A total of 9–10 day 1 adult animals were
scored per genotype.
Microscopy
For confocal images, animals were immobilized on 2%
agar pads with 20 mM NaN3 and imaged with Zeiss
LSM700 microscope at Cell Imaging Center, Drexel Uni-
versity. Z-stacks were acquired at 0.4 μm intervals as 12-
bit images, using 63 × 1.4NA objective, and analyzed
with ImageJ [127].
For the quantification of autophagic vesicles, Z-stacks
were collapsed as maximum intensity projections, the
muscle cells were outlined, and the GFP::LGG-1-positive
puncta within the outlined cells were counted. Thirty to
40 cells from 8 to 10 L4 animals were analyzed per
genotype. To compare GFP::UNC-54 protein levels, GFP
fluorescence was measured within the same size area (~
9 μm2) in the center of each analyzed muscle cell, over
the myofilaments. Sixteen to 20 cells from 4 to 5 animals
per genotype were measured. An identical size area
measured away from the myofilaments was used for
background subtraction.
Fluorescent recovery after photobleaching (FRAP) was
performed on day 2 adults (for aggregated Q40) and L4
larvae (for soluble Q40) animals, as in [90], using the
Zeiss LSM700 confocal microscope. Photobleaching was
performed with 488 nm laser, by 100 iterations at 100%
laser power. Imaging during recovery was at 0.3% power.
Relative fluorescence intensity (RFI) was determined
with the following equation: RFI = (Tt/Ct)/(T0/C0), with
T0 representing the total intensity of the region of inter-
est before photobleaching and Tt the intensity in the
same area at any time after. We normalized against an
unbleached area in the same cell, where C0 is a control
area before bleaching and Ct represents any time after
bleaching [90]. Seven to 18 aggregates from 3 animals
each were measured per strain for aggregated Q40, and
5 cells from 2 animals each were measured per strain for
the soluble Q40 controls.
For stereo images, animals were immobilized on NGM
plates in a drop of 20 mM NaN3. Imaging was per-
formed using a Leica M205FA stereo microscope with
an Orca R2 digital camera (Hamamatsu). The magnifica-
tion and the intensity of fluorescent sources (Chroma
PhotoFluor 2) were kept constant within experiments.
UbG76V::Dendra2 animals were imaged with a narrow-
bandpass CFP filter (Chroma), to avoid the spectral
overlap with the Q40::YFP protein.
Native protein extracts
To prepare native protein extracts, synchronized em-
bryos were isolated by hypochlorite treatments and lar-
vae were collected once they reached the L3 stage.
Worms were washed and allowed to settle on ice, and
the packed pellets were flash frozen after removal of
supernatant. The worm pellets were mechanically dis-
rupted and lysed in 0.5% Triton-X 100 buffer as de-
scribed in [39]. For SDS solubility, native protein
extracts were incubated in 5% SDS for 15 min at room
temperature prior to running on a 5% continuous native
gel, at 25 mg of total protein per lane. Gels were imaged
on a Typhoon FLA7000 scanner (General Electric, USA)
with ImageQuant TL software to quantify YFP fluores-
cence. All experiments were performed three times.
qPCR
Approximately 50 μl pellets of L4 stage worms were flash
frozen in liquid nitrogen, and RNA extraction was per-
formed using TRIzol (Life Technologies, USA) and
chloroform (Sigma, USA) reagents. The samples were
treated with DNase (DNA-free, Life Technologies, USA)
to remove any genomic DNA, and iScript cDNA synthe-
sis kit (Bio-Rad, USA) was used to reverse transcribe 1–
2 μg of RNA per sample. The expression of selected
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genes was measured using iTaq Universal SYBR Green
Supermix (Bio-Rad) and the ViiA detector (Applied Bio-
systems). Each biological replicate was run in triplicate,
and data analyzed using the ΔΔCT method [128]. Three
biological replicates were used to assess statistical signifi-
cance. Gamma-tubulin (tbg-1) was used for normalization,
as it was stable between the drxIR1 and the Bristol strains.
Sequences for tbg-1 primers were as in ref. [129]. Primer
sequences are listed in Additional file: Table S3.
RNAi experiments and constructs
For RNAi experiments, NGM plates containing 100 μg/
ml ampicillin and 0.4 mM IPTG were seeded with con-
trol (L4440 empty vector, unless otherwise noted) or ex-
perimental overnight RNAi bacterial cultures and
incubated at room temperature for 2 days prior to use.
Worms were cultured on the RNAi plates from gastrula
stage embryos for two generations. RNAi clones were
from the Ahringer library (J. Ahringer, University of
Cambridge, Cambridge, UK), except for those corre-
sponding to mab-20, Y71G12B.18, Y71G12B.33,
Y71G12B.23, Y71G12B.35, drag-1, Y71G12B.31, ubc-3,
tln-1, Y71G12B.25, pghm-1, C53H9.3, tag-96, tub-2,
Y51F10.4, and spe-48; these were made by cloning a
unique 0.8 to 1.2 Kb fragment from each gene into the
L4440 plasmid and transforming into the E. coli strain
HT115. Primer sequences are listed in Additional file:
Table S4. All experiments were repeated three times; the
total (combined) number of animals is indicated in fig-
ure legends.
ABT-737 treatment
Twenty to 40 gastrula stage embryos were grown on
OP50 bacteria for 2 days at 20 °C; nematodes collected,
washed, and exposed to either 0.1% DMSO (Sigma,
USA) as solvent control, or 10 μM ABT-737 (ApexBio,
Taiwan). Earlier exposure to ABT-737 resulted in larval
arrest. Animals were incubated in the drug solution with
shaking for 24 h, pipetted onto plates, and either scored
for aggregation or imaged.
Statistical analyses
ANOVA and t test analyses were performed with Prism
software (GraphPad, USA), using α value of 0.5.
ANOVA was followed by Bonferroni’s multiple compari-
sons post-test. All P values and significance levels are in-
dicated in the figures and figure legends.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12915-020-0750-5.
Additional file 1: Figure S1. Schematic of the drxlR1 interval and SNPs
used for mapping. (A) Red: the 1.4 Mb genomic region on chromosome
I, containing the DR1350-derived intervals, in the RIL2-derived drxlR1;Q40
strain and the four remaining high aggregation RILs (RIL12, RIL12(2),
RIL18 and RIL15); orange: the Bristol background. Punctate lines
delineate the narrowed 326 Kb interval containing the candidate genes
tested by RNAi. Diamonds: SNPs used to test for the presence of the
interval; SNP 6b (ChrI:1,972,719 (WBVar00017376)) is Bristol-derived in
drxIR1;Q40 and RIL15 animals. Locations of egl-30, moag-4 and the
incompatibility locus zeel-1/peel-1are also indicated. The coordinates here
correspond to the WormBase release WS270 [131]. (B) WormBase names
and chromosomal locations of SNPs marked with diamonds in A.
Additional file 2: Figure S2. Cumulative distribution of unique SNPs
across remaining chromosomes. chromosomes II through X in the
drxlR1;Q40 strain accumulated up to 160 unique SNPs each. Shown are
SNPs remaining after subtraction of the variants present in Q40Bristol
strain, and of variants in the Hawaiian isolate that does not exhibit
increased polyQ40 aggregation.
Additional file 3: Figure S3. Controls for the basal proteostasis effects
of the drxIR1 locus. (A) The UbG76V::Dendra2 proteasome reporter is
sensitive to decreased proteasome levels. Knockdown of a proteasome
subunit rpn-6.1, via RNAi, increased the average intensity of the Dendra2
compared to control treatment. Images were taken and quantified as in
Fig. 2a. Data are mean ± SD. Data were analyzed by unpaired t-test, two-
tailed, *P=0.0244. (B) Stereomicrographs of young adult animals after
treatment with control or moag-4 RNAi. moag-4 RNAi decreased
aggregation in both backgrounds, but preserved the increased
aggregation drxIR1;Q40 animals relative to Q40Bristol.
Additional file 4: Figure S4. The drxIR1 interval decreases accumulation
of polyQ67 aggregates in the neurites. (A) Outline of the head of an
individual animal, with intestine (int) and pharynx (ph) indicated. Anterior
to the left, dorsal up. Green shows projection of Q67n::CFP fluorescence
signal overlaid on the transmitted light image. Punctate line in the
middle immediately below the anterior pharyngeal bulb separates the
dendritic region where aggregation was scored (anterior to the line) from
the area with many neuronal cell bodies and the axonal bundle. The
scored region contains mainly dendrites of sensory neurons, with some
interneuron processes and some cell bodies and/or neurites of other
types of neurons (https://www.wormatlas.org/neuronsandcircuits.html).
Scale bar is 20 μm. Same animal as in panel B, top. (B) Confocal images
of heads of two Q67n::CFP animals in Bristol background, rotated into
horizontal positions. Regions scored in Fig 5f are anterior (to the left) to
the punctate line (marked as dendrites). Examples of aggregates within
the neurites are indicated by arrowheads. (C) Confocal images of
drxIR1;Q67n::CFP animals. Labeling as in panel B. Areas marked as cell
bodies and axons did not exhibit decreased aggregation in drxIR1
background relative to Bristol (compare to the same area in panel B). (D,
E) Same images as in panels B and C, respectively, shown with enhanced
fluorescence.
Additional file 5: Table S1. Loss-of-function analysis for the RIL2-like
head aggregation phenotype. sDP2 free duplication covers most of the
left arm of chromosome I, extending through dpy-5 marker but not
through unc-13. drxIR1;Q40 animals were crossed with KR292 [him-
1(h55);dpy-5(e61);unc-13(e450)I; sDp2(I;f)], F1 progeny that either did
(based on segregation of unc non-dpy phenotype among their progeny)
or did not inherit the sDp2 duplication were singled, and their F2
progeny scored for the increased ratio of head to body aggregation
(RIL2-like) and the dumpy phenotypes. The RIL2-like phenotype behaved
genetically as did the known loss-of-function dpy-5(e61) allele.
Additional file 6: Table S2. Candidate genes tested by RNAi. 24
candidate genes present in the target 326 Kb of drxIR1 interval (between
SNPs 5 and 6b (Additional file 1: Fig. S1)) are indicated in color. Genes
were defined as candidates based on the SnpEff annotations (see
Methods and Additional file: Data File 1). egl-30 was excluded based
on genetic crosses. Genes in purple were targeted by clones from the
Ahringer RNAi library. RNAi targeting constructs for genes in red were
prepared in this work.
Additional file 7: Table S3. Primers used for genotyping the drxIR1
locus and for qPCR analysis of atg-5 expression.
Additional file 8: Table S4. Primers used for generating RNAi clones.
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Additional file 9: Data File 1. List of genes in the drxIR1 interval with
potentially significant SNPs generated by the SnpEff tool. The nucleotide
positions correspond to the N2(Bristol) genome assembly from
WormBase release WS220 [131], available in the UCSC Genome Browser
as ce10. The presence of human orthologs is according to [132].
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